Balentine LLC’s Royalty Pharma RPRX Stock Holding History

Balentine LLC’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,934	Closed	-$286K	–	633
2023 Q1	$286K	Buy	+7,934	New	+$294K	0.01%	424

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balentine LLC's RPRX Position: Q2 2023 in Review

Balentine LLC sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 7,934 shares — an estimated $286K sold.

Balentine LLC first reported a position in RPRX in Q1 2023 and held it in 1 quarter. The position peaked at $286K in Q1 2023. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Balentine LLC reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Balentine LLC sold 7,934 Royalty Pharma shares in Q2 2023, an estimated $286K.
Balentine LLC first reported a position in Royalty Pharma in Q1 2023 and held it in 1 quarter.
Balentine LLC's Royalty Pharma position peaked at $286K in Q1 2023.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Balentine LLC's 13F filing for Q2 2023, filed 14 Aug 2023.